BOTHELL, Wash.--(BUSINESS WIRE)--
Seattle Genetics, Inc. (SGEN) today announced the initiation of a phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with RCHOP (A+RCHOP), the current standard frontline therapy, for newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). The study is intended to evaluate the complete remission rate and safety of the A+RCHOP regimen. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30. ADCETRIS is currently not approved for the treatment of DLBCL.
The encouraging data we have observed in our phase 2 trial of ADCETRIS in relapsed non-Hodgkin lymphoma, including DLBCL patients, support evaluation in earlier lines of therapy for patients with this aggressive lymphoma type, said Clay B. Siegall., Ph.D., President and Chief Executive Officer at Seattle Genetics. This trial will provide us with data on the tolerability of the combination, as well as the antitumor activity achieved by adding ADCETRIS to the current standard frontline regimen. In addition, based on interim findings from our trial in the relapsed setting in which objective responses were observed among patients with low or undetectable levels of CD30 by conventional screening methods, we will enroll high-risk DLBCL patients to this frontline trial without prescreening for CD30 expression.
In this phase 2, open-label clinical trial, approximately 50 frontline high-risk DLBCL patients will receive ADCETRIS in combination with the standard of care consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (A+RCHOP). Patients will be randomized to receive standard dose RCHOP with either 1.2 milligrams per kilogram (mg/kg) or 1.8 mg/kg of ADCETRIS. The trial will enroll patients regardless of CD30 expression level by immunohistochemistry (IHC) to further explore previously reported interim data from an ongoing phase 2 trial for relapsed B-cell lymphomas, including DLBCL, demonstrating objective responses in patients with varying levels of CD30. The primary endpoints are to assess the complete remission rate and safety profile of the combination. Secondary endpoints include objective response rate, progression-free survival and overall survival.
At the International Conference on Malignant Lymphoma in June 2013, data were presented from an ongoing phase 2 trial for relapsed B-cell lymphomas that included 44 relapsed patients who received single-agent ADCETRIS, including 25 with DLBCL. Among DLBCL patients, the objective response rate was 44 percent (11 of 25), including 20 percent complete remissions and 24 percent partial remissions. Eighty-one percent of patients achieved tumor reduction. Among 44 B-cell lymphoma patients enrolled, the most common treatment-emergent adverse events were neutropenia (43 percent), fatigue (36 percent), nausea (34 percent) and diarrhea (32 percent). The most common Grade 3 or 4 adverse events were neutropenia (25 percent Grade 3; 11 percent Grade 4) and anemia (9 percent Grade 3).
More information about the ongoing phase 2 frontline or relapsed DLBCL trials, including enrolling centers, is available by visiting http://www.clinicaltrials.gov.
About Diffuse Large B-Cell Lymphoma
Lymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Non-Hodgkin lymphoma (NHL) represents a diverse group of cancers that develop in the lymphatic system and are characterized by uncontrolled growth and accumulation of abnormal lymphocytes. Lymphocytes are a type of white blood cells that are responsible for defending the body against infection. The most common forms of NHL are follicular (slow growth) and diffuse large B-cell lymphoma (a faster growing sub-type).
About ADCETRIS
ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.
- ACT - Stem Cell Trial for AMD and Stargardt - Phase 1 [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Excerpt from: "The Urban Wire" Internet Radio Podcast: FDA Oks embryonic stem cell trials for humans [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Advanced Cell Technology (ACT) AMD stem cell clinical phase [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Stem Cells Retina and cornea regeneration ACT Dr lanza - Advanced Cell Technology [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Spinal Patient Receives Stem Cells in First Experimental Treatment [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Bloomberg: Geron, StemCells Rise 4% [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Bringing Stem Cell Cures to the Clinic: UC Davis GMP Facility [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Researchers in California Show Results for Spinal Cord Injuries Using Embryonic Stem Cells [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Bill Caldwell, Chairman [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Advanced Cell Technology OneMedForum 2011 [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- ACT edmund vision stem cells program Advanced Cell Technology [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Texans for Stem Cell Research Learn for Life: KXAN Coverage Aired August 16th, 2011 [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- ACT - Dr Lanza - Hermangioblast program - Advanced cell technology [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Anticipating the Next Decade of the Genome - Francis Collins, Director of NIH [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- New Epilepsy Treatment Under Study For Seizures - Part 1 [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- A Thank You For Trevor Raborn [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- CBLI Breaking News [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- What is Cord Blood Banking? The Medical Potential of Newborn Stem Cells [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Stem cell medical breakthrough? [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- NIST Colloquium Series: Next Generation Neural Implants [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Alan Lewis: Embryonic Stem Cell Therapies for diabetes [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- 2011 Predictions for Hair Transplant Developments | Arocha Hair Restoration [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Healthbeat - Stem Cell Research [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Living With ALS [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- A Revolutionary New Potential Treatment for Glioblastoma... [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Lyme Disease: Challenges and Innovations [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- 2010: Cord blood saving lives [CNN: 5-30-2011] [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Biotechnology, Diagnostics, and Genomics: Panel Discussion [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Pharmacogenomics [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Brickheads - Osteobots Practice Skit.mpg [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- A veteran lives with ALS [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- Healthy Body = Functional Body. Hollywood Look Side Effect: Healthy Function [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- 2009 Flu Summit: Opening Remarks [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- Cord Blood Breakthrough [Last Updated On: September 28th, 2011] [Originally Added On: September 28th, 2011]
- SENS5 - Leucocyte transfusions as a novel immunotherapy for cancer patients [Last Updated On: October 2nd, 2011] [Originally Added On: October 2nd, 2011]
- Lymphoma Drug SGN-35 - The Nebraska Medical Center [Last Updated On: October 2nd, 2011] [Originally Added On: October 2nd, 2011]
- ACell Hair Restoration with Dr. Gary Hitzig and Dr. Amiya Prasad - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- Hans Keirstead: Developing therapies based on embryonic stem cells - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- NJN News Healthwatch Report - Cornea Treatment Study - Video [Last Updated On: October 20th, 2011] [Originally Added On: October 20th, 2011]
- HIV/AIDS may be prevented by new lubricant - Video [Last Updated On: October 22nd, 2011] [Originally Added On: October 22nd, 2011]
- MFIII Switzerland PE Sheep Placenta Glandular therapy Study - Client Interviews - Video [Last Updated On: October 22nd, 2011] [Originally Added On: October 22nd, 2011]
- Love Diabetes: BCG and Noncompliant Patients - Video [Last Updated On: October 25th, 2011] [Originally Added On: October 25th, 2011]
- Dr. Alimorad Farshchian statement on embryonic stem cells - Video [Last Updated On: October 27th, 2011] [Originally Added On: October 27th, 2011]
- StemCellTV Daily Report-October 29, 2011 - Video [Last Updated On: October 30th, 2011] [Originally Added On: October 30th, 2011]
- Stephen McKenna MD - 8 - Video [Last Updated On: October 31st, 2011] [Originally Added On: October 31st, 2011]
- ALS Stem Cell Trial at Emory - Video [Last Updated On: November 22nd, 2011] [Originally Added On: November 22nd, 2011]
- Target Product Profile: Ellen Feigal - 2011 CIRM Grantee Meeting - Video [Last Updated On: December 6th, 2011] [Originally Added On: December 6th, 2011]
- Monoclonal Antibodies: Stanford Academia-Industry Collaboration - Video [Last Updated On: December 8th, 2011] [Originally Added On: December 8th, 2011]
- Parkinson's Disease Guidelines (Part 2) - Video [Last Updated On: December 9th, 2011] [Originally Added On: December 9th, 2011]
- Macular Degeneration Drugs - Video [Last Updated On: December 13th, 2011] [Originally Added On: December 13th, 2011]
- BrainStorm Cell Therapeutics (OTCBB:BCLI) Has Potentially Developed A Treatment For ALS [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- StemCells, Inc. Receives FDA Authorization for Age-Related Macular Degeneration Clinical Trial [Last Updated On: February 3rd, 2012] [Originally Added On: February 3rd, 2012]
- Stemedica Cell Technologies - Documentary - Video [Last Updated On: February 4th, 2012] [Originally Added On: February 4th, 2012]
- (GMCR, STEM, DSCO) CRWENewswire.com Stocks In Action - Video [Last Updated On: February 7th, 2012] [Originally Added On: February 7th, 2012]
- Bioheart Acquires Exclusive Rights to Ageless Regenerative Institute's Adipose Cell Technology [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- Neuralstem Announces Closing of $5.2-Million Registered Direct Offering [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- Scientists Repair Heart Attack Damage Using Patient's Own Stem Cells To Regrow Healthy Heart Muscle [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- Stem Cells Regrow Healthy Heart Muscle In Heart Attack Patients [Last Updated On: February 15th, 2012] [Originally Added On: February 15th, 2012]
- Groundbreaking Clinical Trials Study Cord Blood Stem Cells to Help Treat Brain Injury and Hearing Loss [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- Novelos Therapeutics Announces Enrollment of First Patient in Lung Cancer Trial With I-124-CLR1404 (Light) Cancer ... [Last Updated On: February 22nd, 2012] [Originally Added On: February 22nd, 2012]
- IntelliCell BioScience Inc. Procedure Enables Norwegian Star Basketball Player to Fully Recover from Patella ... [Last Updated On: February 22nd, 2012] [Originally Added On: February 22nd, 2012]
- The Lancet Publishes Results from Gentium's Phase III Defibrotide Trial for the Prevention of VOD in Paediatric Patients [Last Updated On: February 27th, 2012] [Originally Added On: February 27th, 2012]
- Bioheart Issues Shareholder Letter Announcing Progress and New Initiatives [Last Updated On: March 1st, 2012] [Originally Added On: March 1st, 2012]
- Bioheart Issues Shareholder Letter Announcing Progress [Last Updated On: March 1st, 2012] [Originally Added On: March 1st, 2012]
- Novelos Therapeutics and Academic Collaborators Have Three Abstracts Accepted for Presentation at 2012 AACR Annual ... [Last Updated On: March 1st, 2012] [Originally Added On: March 1st, 2012]
- Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344 [Last Updated On: March 6th, 2012] [Originally Added On: March 6th, 2012]
- Will StemCells Walk The Talk? [Last Updated On: March 7th, 2012] [Originally Added On: March 7th, 2012]
- Internationally Recognized Leukemia Physician and Researcher to Lead Sylvester Comprehensive Cancer Center [Last Updated On: March 7th, 2012] [Originally Added On: March 7th, 2012]
- Criminal investigation after patient dies at office of doctor linked to stem cell [Last Updated On: March 9th, 2012] [Originally Added On: March 9th, 2012]
- Novelos Therapeutics Announces Enrollment of First Patient in Brain Cancer Trial with I-124-CLR1404 (LIGHT) Cancer ... [Last Updated On: March 15th, 2012] [Originally Added On: March 15th, 2012]
- Vitro Biopharma Receives Approval for Presentation to the International Society for Cellular Therapy [Last Updated On: March 20th, 2012] [Originally Added On: March 20th, 2012]
- Looking for Innovative Small-Cap Biotech Companies: George Zavoico [Last Updated On: March 26th, 2012] [Originally Added On: March 26th, 2012]
- Seattle Genetics Announces Pivotal ADCETRIS™ (Brentuximab Vedotin) Hodgkin Lymphoma Study Published in Journal of ... [Last Updated On: March 27th, 2012] [Originally Added On: March 27th, 2012]
- Gentium Reports Fourth Quarter and Year End 2011 Financial Results [Last Updated On: March 28th, 2012] [Originally Added On: March 28th, 2012]
- Basketball’s influence on stem cell treatments in sports medicine [Last Updated On: March 30th, 2012] [Originally Added On: March 30th, 2012]
- Cardium Announces U.S. Market Introduction of Excellagen™ [Last Updated On: March 31st, 2012] [Originally Added On: March 31st, 2012]
- Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult ... [Last Updated On: March 31st, 2012] [Originally Added On: March 31st, 2012]
- New Data Demonstrates DIFICLIR™ May Offer Benefits for Cancer Patients, who are at High Risk of Clostridium Difficile ... [Last Updated On: April 1st, 2012] [Originally Added On: April 1st, 2012]
- SynGen Inc. Receives $5 million Equity Investment from Bay City Capital, LLC [Last Updated On: April 19th, 2012] [Originally Added On: April 19th, 2012]
- Gene Ray, Founder of $2.6 Billion Titan Corp, Invests in Medistem's ERC Technology and Joins Advisory Board [Last Updated On: April 26th, 2012] [Originally Added On: April 26th, 2012]